CARBOGEN AMCIS Shanghai site clears unannounced NMPA GMP inspection

Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China

Carbogen Amcis announces refinancing and enhancement of syndicated credit facilities

The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million

Celonic and Carbogen Amcis partner to deliver ADC development and manufacturing platform

Carbogen Amcis enters into a co-investment agreement of CHF 25+ million to expand Swiss sites

This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021

Carbogen Amcis Shanghai site receives drug manufacturing license from Chinese NMPA

Carbogen Amcis appoints Stephan Fritschi as CEO

Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.

Carbogen Amcis successfully completed Swissmedic inspection of its Vionnaz facility

The site’s GMP Certification has been successfully renewed

USFDA successfully inspects Carbogen Amcis’s manufacturing sites in Neuland and Aarau

The inspections concluded with no Form 483 observations or significant critical findings

Carbogen Amcis (Shanghai) completed ANVISA Audit

A five-day inspection was concluded successfully with no critical and no major observations raised

Dishman Carbogen Amcis updates on USFDA inspection at its Bavla facility

The inspection was concluded with few procedural observations